## Contents

*List of contributors* vii  
*Preface* xi  

### Section 1 – General aspects

1. **Overview of Parkinson’s disease: epidemiology, diagnosis, course, medical and surgical management**  
Sheila R. Eichenseer and Christopher G. Goetz  

2. **Parkinson’s disease: pathology, anatomy, and behavior**  
Daniel J. Burdick and James B. Leverenz  

3. **The genetics of behavior and cognition in Parkinson’s disease**  
Caroline H. Williams-Gray and Roger A. Barker  

4. **The boundaries of Parkinson’s disease dementia and dementia with Lewy bodies**  
Elisabet Londos  

### Section 2 – Diagnosis and biomarkers

5. **Cognitive assessment in Parkinson’s disease**  
Jaime Kulisevsky, Saúl Martínez-Horta, and Javier Pagonabarraga  

6. **Clinical assessment: mood and motivation**  
Albert F. G. Leentjens  

7. **Imaging and behavior in Parkinson’s disease: structural imaging**  
Mona K. Beyer, Turi O. Dalaker, and Liana G. Apostolova  

8. **Imaging and behavior in Parkinson’s disease: functional imaging**  
Agneta Nordberg  

9. **Diagnosis and biomarkers: CSF**  
Brit Mollenhauer and Henrik Zetterberg  

### Section 3 – Specific neuropsychiatric disorders

10. **Depression**  
Per Svenningsson and Dag Aarsland  

11. **Anxiety**  
Laura Marsh and Jessica Calleo  

12. **Apathy**  
Kathy Dujardin  

13. **Impulse control disorders and related behaviors**  
Daniel Weintraub and Irena Rektorova  

14. **Psychosis**  
Oscar Bernal-Pacheco and Hubert H. Fernandez  

15. **Early cognitive impairment**  
Alexander I. Tröster and Dag Aarsland  

16. **Parkinson’s disease dementia**  
Başar Bilgiç, Hașmet A. Hanagaşı, and Murat Emre  

17. **Sleep disturbances**  
Pouya Movahed, Kristina Røkenes Karlsen, and K. Ray Chaudhuri  

### Section 4 – Management

18. **Drug treatment and behavior**  
Jaime Kulisevsky, Javier Pagonabarraga, and Carolina Villa-Bonomo
## Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>2</td>
<td>Surgical treatment and behavior</td>
<td>230</td>
</tr>
<tr>
<td></td>
<td>Jens Volkmann and Christine Daniels</td>
<td></td>
</tr>
<tr>
<td>20</td>
<td>Clinical trials for psychotropic agents in Parkinson’s disease using psychosis as a model</td>
<td>244</td>
</tr>
<tr>
<td></td>
<td>Ryan R. Walsh and Jeffrey Cummings</td>
<td></td>
</tr>
<tr>
<td>21</td>
<td>The impact of neuropsychiatric symptoms on quality of life in Parkinson’s disease</td>
<td>255</td>
</tr>
<tr>
<td></td>
<td>Angelo Antonini and Pablo Martinez-Martin</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Neuropsychiatric and cognitive disorders in other parkinsonian disorders</td>
<td>261</td>
</tr>
<tr>
<td></td>
<td>Adam Gerstenecker, Benjamin T. Mast, and Irene Litvan</td>
<td></td>
</tr>
<tr>
<td>23</td>
<td>Neuropsychiatric aspects of the on/off phenomenon</td>
<td>275</td>
</tr>
<tr>
<td></td>
<td>Irena Rektorova and Marek Balaz</td>
<td></td>
</tr>
<tr>
<td>24</td>
<td>Treatment of neuropsychiatric disturbances in Parkinson’s disease: future prospects and strategies</td>
<td>285</td>
</tr>
<tr>
<td></td>
<td>Jeffrey Cummings and Dag Aarsland</td>
<td></td>
</tr>
</tbody>
</table>

---

Section 5 – Other issues

<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>21</td>
<td>The impact of neuropsychiatric symptoms on quality of life in Parkinson’s disease</td>
<td>255</td>
</tr>
<tr>
<td></td>
<td>Angelo Antonini and Pablo Martinez-Martin</td>
<td></td>
</tr>
<tr>
<td>22</td>
<td>Neuropsychiatric and cognitive disorders in other parkinsonian disorders</td>
<td>261</td>
</tr>
<tr>
<td></td>
<td>Adam Gerstenecker, Benjamin T. Mast, and Irene Litvan</td>
<td></td>
</tr>
</tbody>
</table>

---

Color plates will be found between pages 148 and 149